ArticleAnnals of Saudi medicine
Clinical pathway implementation for adult sickle cell vaso-occlusive crises: Impact on healthcare utilization, opioid prescribing, and costs.
Article in Annals of Saudi medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVaso-occlusive crisis (VOC) is the leading cause of emergency department (ED) visits and hospitalization in sickle cell disease (SCD). Standardized clinical pathways may improve care quality and reduce healthcare utilization, yet regional evidence from Saudi Arabia remains limited.
objectivesTo evaluate the clinical and economic impact of a multidisciplinary clinical pathway on VOC management, opioid prescribing, and direct healthcare costs.
designRetrospective before-and-after cohort study.
settingSingle-center, 500-bed tertiary referral hospital in Jeddah, Saudi Arabia. PATIENTS AND
methodsAdults (≥12 years) with confirmed SCD (HbSS, HbSC, or HbS/β-thalassemia) presenting with isolated VOC were included. Outcomes were compared across two consecutive 12-month periods before (May 2016-April 2017) and after (May 2017-April 2018) pathway implementation.
main outcome measuresAnnual ED visits, hospital admissions, 7-day readmission rate, opioid consumption, length of stay, and direct cost savings. SAMPLE SIZE: 316 unique patients pre-implementation and 374 post-implementation.
resultsVOC-related ED visits decreased by 69.7% (14,273 vs. 4,319;
conclusionsImplementation of a multidisciplinary VOC clinical pathway was associated with substantial reductions in healthcare utilization, hospital stay, readmissions, and direct costs, while promoting evidence-based opioid prescribing in adults with SCD. LIMITATIONS: Single-center, uncontrolled before-and-after design without adjustment for genotype imbalance between cohorts; incomplete pathway adherence in some clinical areas; patient-reported outcomes were not collected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.